Theriva Biologics receives FDA Rare Pediatric Drug Designation for VCN-01 in retinoblastoma

Theriva Biologics, Inc.

FDA grants Rare Pediatric Drug Designation for VCN-01, a stroma-degrading oncolytic adenovirus, to treat retinoblastoma.
Prior orphan drug designation for same indication; RPDD may provide a Priority Review Voucher upon BLA approval.
Holders of Series C Convertible Preferred Stock converted 135,431 shares into 888,072 common shares at $1.22 per share.
Positive Phase 1 results from investigator-sponsored trial of intravitreal VCN-01 in pediatric refractory retinoblastoma inform clinical pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.